Famotidine

The exact human strengths have current, traceable registrations in Georgia and Hungary, official product documents and an identifiable manufacturer. No veterinary famotidine product was found in the checked VMD register, so dog and cat use of these human tablets is off-label.

Controlled canine pH studies show short-term acid suppression with twice-daily famotidine, but it is inferior to omeprazole and repeated dosing loses effect within days; direct clinical healing-outcome evidence is limited and once-daily or empirical antiemetic use is unsupported.

Famotidine is generally well tolerated and the exact human label provides established contraindication, adverse-effect, interaction and renal-adjustment information. Veterinary use remains off-label; exposure rises with renal impairment, reproductive safety is not established for these animal uses, and prolonged treatment adds tolerance and rebound concerns.

At 0.5 mg/kg twice daily, one whole 20 mg tablet corresponds to about a 40 kg dog. The current exact SPC describes whole swallowing and no validated score; smaller dogs usually need another strength or a pharmacy-compounded formulation, while twice-daily home administration is otherwise simple.

The exact human strengths have current, traceable registrations in Georgia and Hungary, official product documents and an identifiable manufacturer. No veterinary famotidine product was found in the checked VMD register, so dog and cat use of these human tablets is off-label.

A small controlled feline crossover study shows twice-daily oral famotidine raises intragastric pH above placebo, but it is inferior to omeprazole. Evidence is mainly short-term physiology in healthy cats, tolerance develops with repeated use, and clinical healing outcomes remain uncertain.

Famotidine is generally well tolerated and the exact human label provides established contraindication, adverse-effect, interaction and renal-adjustment information. Veterinary use remains off-label; exposure rises with renal impairment, reproductive safety is not established for these animal uses, and prolonged treatment adds tolerance and rebound concerns.

The studied feline dose is about 0.88-1.26 mg/kg twice daily, roughly 3.5-5 mg for a 4 kg cat. A whole-only 20 mg tablet cannot deliver that dose accurately; use an appropriate lower-strength or pharmacy-compounded formulation rather than estimating fragments or crushed powder.

The exact human strengths have current, traceable registrations in Georgia and Hungary, official product documents and an identifiable manufacturer. No veterinary famotidine product was found in the checked VMD register, so dog and cat use of these human tablets is off-label.

Controlled canine pH studies show short-term acid suppression with twice-daily famotidine, but it is inferior to omeprazole and repeated dosing loses effect within days; direct clinical healing-outcome evidence is limited and once-daily or empirical antiemetic use is unsupported.

Famotidine is generally well tolerated and the exact human label provides established contraindication, adverse-effect, interaction and renal-adjustment information. Veterinary use remains off-label; exposure rises with renal impairment, reproductive safety is not established for these animal uses, and prolonged treatment adds tolerance and rebound concerns.

At 0.5 mg/kg twice daily, one whole 40 mg tablet corresponds to about an 80 kg dog. The current exact SPC describes whole swallowing and no validated score, so this strength rarely fits a canine dose without an accurately compounded alternative.

The exact human strengths have current, traceable registrations in Georgia and Hungary, official product documents and an identifiable manufacturer. No veterinary famotidine product was found in the checked VMD register, so dog and cat use of these human tablets is off-label.

A small controlled feline crossover study shows twice-daily oral famotidine raises intragastric pH above placebo, but it is inferior to omeprazole. Evidence is mainly short-term physiology in healthy cats, tolerance develops with repeated use, and clinical healing outcomes remain uncertain.

Famotidine is generally well tolerated and the exact human label provides established contraindication, adverse-effect, interaction and renal-adjustment information. Veterinary use remains off-label; exposure rises with renal impairment, reproductive safety is not established for these animal uses, and prolonged treatment adds tolerance and rebound concerns.

The studied feline dose is about 0.88-1.26 mg/kg twice daily, roughly 3.5-5 mg for a 4 kg cat. A whole-only 40 mg tablet is profoundly mismatched and cannot deliver that dose accurately; an appropriate lower-strength or pharmacy-compounded formulation is required.

The exact 20 mg vial, 5 ml solvent, 4 mg/ml reconstituted concentration, holder and IV-only human label are traceable in current GE and Lithuanian records. Veterinary use is off-label and no exact veterinary dossier exists.

Randomised healthy-dog IV pH studies show significant short-term acid suppression; a high-dose CRI met human-derived healing pH targets, while intermittent dosing did not. No diseased-dog healing, bleeding, quality-of-life or exact-product outcome trial exists.

Human exact-label safety and veterinary class experience are substantial, but exact-product dog repeated-dose, diseased-subgroup and reproductive data are absent. Renal accumulation, hypersensitivity, infusion handling and route-related events require review.

The supplied solvent creates a known 4 mg/ml solution suitable for monitored IV measurement, but use requires reconstitution, hospital administration, slow injection or infusion, asepsis, compatibility review and immediate microbiological use. Exact-product SC administration is unsupported.

The exact 20 mg vial, 5 ml solvent, 4 mg/ml reconstituted concentration, holder and IV-only human label are traceable in current GE and Lithuanian records. Veterinary use is off-label and no exact veterinary dossier exists.

Cats have controlled oral pH evidence showing short-term effect inferior to omeprazole and route-specific IV safety exposure, but no feline injectable pH-efficacy or clinical-healing trial. Efficacy of this exact IV product is therefore indirect.

In 142 hospitalised cats, slow IV famotidine was not associated with haemolysis or a greater PCV decline than SC or control exposure, directly addressing a common concern. This retrospective study does not establish all uncommon, repeated-dose, reproductive or exact-product risks.

The supplied solvent creates a known 4 mg/ml solution suitable for monitored IV measurement, but use requires reconstitution, hospital administration, slow injection or infusion, asepsis, compatibility review and immediate microbiological use. Exact-product SC administration is unsupported.